Ironwood Pharmaceuticals
IRWD
226 hedge funds and large institutions have $1.12B invested in Ironwood Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 93 increasing their positions, 79 reducing their positions, and 52 closing their positions.
39,455% more call options, than puts
Call options by funds: $73.6M | Put options by funds: $186K
18% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 79
2.32% less ownership
Funds ownership: 110.12% → 107.8% (-2.3%)
13% less funds holding
Funds holding: 261 → 226 (-35)
26% less capital invested
Capital invested by funds: $1.5B → $1.12B (-$383M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
60% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 52
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$17M |
| 2 |
Morgan Stanley
New York
|
+$15.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.4M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$12M |
| 5 |
Renaissance Technologies
New York
|
+$10.4M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$33.1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$9.79M |
| 3 |
BlackRock
New York
|
-$9.06M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.4M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.83M |
IRWD Hedge Fund Activity: Q2 2024 in Review
226 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2024, worth a combined $1.12B — down 26% from $1.5B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of IRWD and 21 opened new positions — a net loss of 31 holders — while 79 trimmed existing stakes and 93 added.
The largest buyer was Armistice Capital, adding an estimated $17M. The largest seller was State Street, cutting an estimated $33.1M.
- 226 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2024, down from 261 in Q1 2024.
- Funds reported $1.12B of Ironwood Pharmaceuticals stock for Q2 2024, down 26% quarter-over-quarter.
- 21 funds opened new Ironwood Pharmaceuticals positions in Q2 2024 and 52 closed out, a net change of -31 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $17M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2024 was State Street, an estimated $33.1M sold.
Based on aggregated 13F filings for Q2 2024.